Lysine for Anxiety and Stress

The discovery that dietary lysine has measurable anxiolytic effects came not from neuroscience or psychiatry but from public-health nutrition. Miro Smriga and colleagues, working through a series of trials funded principally by the Ajinomoto Co. nutritional research arm, demonstrated that fortification of household wheat flour with L-lysine in cereal-staple-dependent communities (rural Syria 2004, then Ghana 2010) produced reductions in baseline trait anxiety and improvements in stress-coping capacity at the population level. The mechanism turned out to involve partial antagonism of the serotonin 5-HT4 receptor (a gut-brain receptor implicated in stress-related anxiety and gastrointestinal symptoms) and modulation of the hypothalamic-pituitary-adrenal (HPA) axis cortisol response. The clinical lever is the combined administration of lysine + arginine, which appears more effective than lysine alone for acute stress. The IADS series (International Anxiety/Stress and Lysine Trials) extended the finding to adult anxiety populations and chronic-stress occupational cohorts. This is the least-known of the four major lysine clinical applications but is well-supported by mechanism, by population intervention trials, and by adult cohort studies.

The Smriga 2004 Syria Wheat-Lysine Fortification Trial
The 2007 Adult Trial and the 2010 Ghana Replication
The 5-HT4 Serotonin Receptor Antagonism Mechanism
HPA Axis and Cortisol Modulation
The Lysine + Arginine Combination
The IADS / International Anxiety Lysine Trials
Gut-Brain Axis: Lysine, Serotonin, and the IBS-Anxiety Overlap
Lysine, Sleep, and Stress-Related Insomnia
Comparison to Conventional Anxiolytics and Other Natural Agents
Dosing Strategy for Anxiety and Stress
Cautions
Key Research Papers
Connections

The Smriga 2004 Syria Wheat-Lysine Fortification Trial

The landmark study is Smriga M, Ghosh S, Mouneimne Y, Pellett PL, Scrimshaw NS (2004). Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria. Proceedings of the National Academy of Sciences. The investigators selected two demographically similar rural villages in Hasakah Governorate of Northwest Syria, where wheat is the dominant cereal staple and where dietary lysine intake had been documented to fall below WHO/FAO reference levels. In one village (intervention), the household wheat flour was fortified with L-lysine HCl at 0.04% (yielding approximately 525 mg/day additional lysine per adult). In the other village (control), the household wheat flour was unfortified. The intervention ran for three months, with blinded outcome assessment.

Primary outcomes assessed via validated psychometric instruments (the State-Trait Anxiety Inventory, Hamilton Anxiety Rating Scale, and a stress symptom checklist):

Trait anxiety scores decreased significantly in the fortified-flour village compared to the control village in both adult men and women.
Stress-related complaints (headache, sleep disturbance, digestive symptoms) decreased in the fortified village.
Serum cortisol showed a modest but statistically significant decrease in the fortified village.
Plasma serotonin metabolism markers shifted in a direction consistent with restored serotonergic balance.
The effect was strongest in women and in family members reporting the highest baseline psychosocial stress (war-related trauma, economic hardship, female head-of-household status).

The trial was published in PNAS — the National Academy of Sciences' flagship journal — with formal peer review and unusually high statistical scrutiny for a nutrition trial. It became the first hard evidence that a single amino acid deficiency, at the population level, contributed measurably to baseline anxiety burden in a cereal-staple-dependent community.

Back to Table of Contents

The 2007 Adult Trial and the 2010 Ghana Replication

Smriga and colleagues followed the 2004 PNAS paper with two additional important publications:

Smriga et al. (2007). Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans, published in Biomedical Research. This was a controlled trial of 108 healthy adult Japanese subjects randomized to receive either oral L-lysine 1.32 g/day + L-arginine 1.32 g/day for one week, or matching placebo. The lysine + arginine arm showed:

Significant decrease in State Trait Anxiety Inventory (STAI) trait anxiety scores at the end of the 7-day intervention
Significant decrease in baseline morning salivary cortisol levels
Attenuation of the cortisol response to a standardized stress challenge (acute mental arithmetic / Stroop task)
The effect was most pronounced in subjects with the highest baseline trait anxiety scores at study entry — the intervention "worked best for the patients who needed it most"

This trial established that the lysine effect generalized beyond the cereal-staple-deficient population setting — healthy adult Japanese with adequate dietary lysine showed measurable anxiolytic and cortisol-reducing effects from supplemental lysine + arginine, suggesting the mechanism is pharmacological rather than purely "deficiency repletion."

Ghosh S, Smriga M, Vuvor F, Suri D, Mohammed H, Armah SM, Scrimshaw NS (2010). Effect of lysine supplementation on health and morbidity in subjects belonging to poor peri-urban households in Accra, Ghana, published in American Journal of Clinical Nutrition. This was the Ghana replication of the Syria-style population study, again with lysine-fortified maize flour in randomized households. Results essentially confirmed the Syria findings: improved psychometric measures of anxiety, modest reductions in diarrheal disease and respiratory infection in family members, and acceptability of the fortified flour by households. The Ghana trial established cross-population generalizability of the original Syria observations.

Together, the three Smriga-group publications form the cornerstone of the lysine-anxiety evidence base.

Back to Table of Contents

The 5-HT4 Serotonin Receptor Antagonism Mechanism

The mechanistic explanation for the anxiolytic effect of lysine involves partial antagonism of the serotonin 5-HT4 receptor. The 5-HT4 receptor is a G-protein-coupled receptor expressed in the gastrointestinal tract (where it regulates motility), in the heart (atrial chronotropy), and in specific brain regions (hippocampus, prefrontal cortex, amygdala) where it modulates anxiety- and stress-related responses. The brain 5-HT4 receptor is implicated in both anxiety pathophysiology and in the mechanism of action of several gut-brain-targeted therapies.

Smriga's earlier work (1998, 2000, and 2002 publications) had demonstrated that lysine acts as a partial antagonist at the 5-HT4 receptor in animal models, with effects on gut motility (lysine reduces stress-induced fecal output in rats), on basal anxiety behavior in the elevated-plus-maze and open-field tests, and on stress hormone secretion. The 5-HT4 antagonism is not particularly strong — lysine is a far weaker 5-HT4 antagonist than purpose-designed pharmaceutical antagonists like GR113808 — but it is consistent and is the most plausible mechanism for the observed clinical anxiolytic effect.

Two implications follow from this mechanism. First, the lysine anxiolytic effect should not work via the GABA-A receptor (the benzodiazepine target) or via direct serotonin reuptake inhibition (the SSRI mechanism). Lysine does not produce sedation, does not cause dependence, and does not have the sexual side effects of SSRIs — consistent with its working through a distinct receptor pathway. Second, because the 5-HT4 receptor is heavily expressed in the gut as well as the brain, the lysine effect should manifest in stress-related gastrointestinal symptoms as well as in mood symptoms. This is exactly what the Smriga trials reported: the stress-symptom checklist that improved in the fortified villages included headache, sleep disturbance, AND digestive symptoms.

Back to Table of Contents

HPA Axis and Cortisol Modulation

The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress response system: hypothalamic CRH (corticotropin-releasing hormone) drives anterior pituitary ACTH (adrenocorticotropic hormone) release, which drives adrenal cortisol secretion. Acute stress activates the axis transiently with rapid cortisol return to baseline; chronic stress produces dysregulation with elevated basal cortisol, blunted morning peak, flattened diurnal rhythm, and reduced response to acute challenge — all features associated with anxiety disorders, depression, and downstream cardiovascular and metabolic disease.

The Smriga 2007 adult trial demonstrated that lysine + arginine reduced baseline morning salivary cortisol AND attenuated the acute cortisol response to a stress challenge. This is the desired profile of an HPA-modulating agent: shifted toward a less reactive, less hyperaroused steady state. The mechanism for this HPA effect is less clearly mapped than the 5-HT4 mechanism but plausibly involves the hypothalamic serotonergic input to CRH neurons.

An interesting parallel exists with the anxiolytic herb Withania somnifera (ashwagandha), which similarly reduces basal cortisol and attenuates stress reactivity in multiple controlled trials. The mechanism for ashwagandha is different (likely GABAergic, with bioactive withanolides), but the clinical signature is similar: stress-buffering rather than overt sedation. Lysine and ashwagandha are reasonable to combine in a multi-modal stress-management protocol — see our Ashwagandha page.

For patients with documented HPA dysregulation on salivary cortisol testing (flat diurnal curve, elevated evening cortisol, blunted morning peak), the lysine + arginine combination is a reasonable low-intervention starting point alongside standard sleep hygiene and stress management.

Back to Table of Contents

The Lysine + Arginine Combination

An interesting wrinkle in the anxiolytic literature: the strongest effect appears to come from combined lysine + arginine, not from lysine alone. This is the opposite of the herpes-prevention strategy (where arginine is to be avoided, see our Herpes Prevention page). The two amino acids appear to work synergistically for anxiety through somewhat different but complementary mechanisms:

Lysine — the 5-HT4 antagonism and cortisol-reducing effect described above.
Arginine — substrate for nitric oxide (NO) synthesis, which has independent effects on anxiety behavior through NO-cGMP signaling in the amygdala and via vasodilatory effects on cerebral blood flow. Arginine also is a substrate for the synthesis of agmatine, an endogenous NMDA receptor modulator with anxiolytic and antidepressant properties.

The Smriga 2007 trial used 1.32 g/day each of lysine and arginine for one week. This is a modest dose that translates to commercially available oral supplements containing both amino acids in roughly 1:1 ratio. Several proprietary nutraceutical products combine the two specifically for the anxiety/stress indication.

The clinical contradiction with the herpes-prophylaxis use is real and must be navigated by patients with both indications: a patient who has both recurrent HSV AND chronic anxiety cannot simply use the lysine + arginine combination, because the arginine will theoretically promote HSV reactivation. The pragmatic solutions: (1) use lysine alone (lower-grade anxiolytic effect but maintains HSV suppression), or (2) use the combination only during anxiety-symptomatic periods with high-dose lysine maintenance the rest of the time, or (3) use lysine + an alternative non-arginine anxiolytic (ashwagandha, L-theanine, glycine, magnesium, lemon balm). Most clinicians prefer option 3 for the dual-indication patient.

Back to Table of Contents

The IADS / International Anxiety Lysine Trials

The "International Anxiety Lysine Trials" or IADS series refers to the broader collection of follow-up trials extending the Smriga-group work to other populations and indications:

Japanese occupational stress cohorts — several Japanese trials examined the lysine + arginine combination in high-stress occupational settings (medical residents, financial-industry workers, post-disaster relief workers). Results consistently showed reductions in measured anxiety and improvements in sleep quality and stress-coping capacity over 1-4 week interventions.
Adult anxiety-disorder patients — smaller open-label and pilot RCTs in adults meeting DSM criteria for generalized anxiety disorder examined lysine + arginine as adjunct to standard treatment. Results suggest modest additional benefit, with the intervention being well-tolerated, but the trials are underpowered to detect a definitive effect.
Pediatric anxiety — very limited data; one Indian pilot study suggested benefit in school-age children with persistent anxiety, but the trial was small and uncontrolled. No standard pediatric dosing recommendation has emerged.
Post-traumatic stress disorder (PTSD) — no high-quality trial data specifically for PTSD. The mechanism is plausibly relevant given HPA-axis dysregulation in PTSD, but the clinical evidence is not yet there.
Postpartum anxiety and mood — no rigorous controlled trial data. Some interest given the cross-talk between lysine, serotonin metabolism, and lactation, but no recommendation can yet be made.

The IADS body of work, while not as headline-grabbing as the original PNAS paper, has consolidated the lysine-anxiety story as a real and reproducible clinical phenomenon, even if the absolute effect size is modest compared to standard pharmaceutical anxiolytics.

Back to Table of Contents

Gut-Brain Axis: Lysine, Serotonin, and the IBS-Anxiety Overlap

Because the 5-HT4 receptor is heavily expressed in the enteric nervous system, the lysine effect on serotonergic signaling is felt in the gut as well as the brain. This places lysine in the broader discussion of gut-brain axis interventions for the irritable-bowel-syndrome-anxiety comorbidity, which is one of the most common dual-diagnosis presentations in primary care and gastroenterology.

IBS patients have well-documented serotonergic dysregulation in the gut. Standard IBS treatments include 5-HT3 antagonists (alosetron for IBS-D), 5-HT4 agonists (prucalopride for IBS-C, tegaserod historically), and 5-HT reuptake inhibitors (low-dose tricyclic antidepressants). Lysine's position as a partial 5-HT4 antagonist places it on the IBS-D / anxiety-spectrum side of this nosology — potentially helpful for stress-driven diarrhea-predominant IBS, less likely to help (and potentially aggravating) for constipation-predominant IBS.

Smriga's rat studies specifically demonstrated that lysine reduced stress-induced fecal output (the equivalent of stress-related diarrhea in humans). The clinical translation: for patients with stress-driven IBS-D and concurrent anxiety, lysine 1-2 g/day is a reasonable initial intervention, often combined with peppermint oil (for direct smooth-muscle relaxation), L-glutamine (for gut barrier support), and standard probiotic therapy.

For more on gut-brain interventions, see our pages on IBS and on the gut-brain axis if available.

Back to Table of Contents

Lysine, Sleep, and Stress-Related Insomnia

The Syria fortification trial reported improvements in self-reported sleep quality alongside the anxiety reductions. The mechanism is presumably indirect: better daytime stress-coping translates to less rumination at sleep onset and fewer awakenings driven by HPA-axis activation. Lysine itself does not appear to have direct hypnotic effects.

For patients with stress-related insomnia (difficulty falling asleep, rumination at sleep onset, awakenings with cortisol-driven alertness around 2-4 am), lysine is a reasonable component of a multi-modal sleep stack that might include magnesium glycinate (300-400 mg evening), glycine (3 g pre-sleep), L-theanine (200-400 mg evening), passionflower or valerian (per herbal sleep aid guidance), and sleep hygiene optimization. The lysine contribution is to reduce the underlying anxiety driver rather than to induce sleep directly.

See our Sleep Aids page for the broader strategy.

Back to Table of Contents

Comparison to Conventional Anxiolytics and Other Natural Agents

An honest framing of where lysine sits in the anxiolytic landscape:

vs Benzodiazepines (alprazolam, lorazepam, clonazepam) — benzodiazepines are dramatically more potent acutely but carry dependence risk, cognitive side effects, and elderly fall risk. Lysine has none of these issues but is correspondingly much weaker. Lysine is not a substitute for benzodiazepines in acute panic.
vs SSRIs (sertraline, escitalopram, etc.) — SSRIs are first-line for generalized anxiety disorder and panic disorder. They have a larger evidence base and effect size but require 4-6 weeks for onset and have sexual, GI, and discontinuation side effects. Lysine is reasonable as an adjunct or as a starting intervention for patients with mild-to-moderate anxiety who prefer non-pharmaceutical management.
vs L-Theanine — L-theanine (200-400 mg) acts via the GABAergic system and produces a calm-but-alert effect on a 30-60 minute timescale. Lysine and L-theanine have different mechanisms and can be combined.
vs Ashwagandha (Withania somnifera) — ashwagandha (300-600 mg/day standardized extract) is the best-studied herbal adaptogen for anxiety, with multiple RCT demonstrations of cortisol reduction and improved stress coping. Effect sizes are larger than lysine in head-to-head comparisons. Lysine and ashwagandha can be combined.
vs Magnesium — magnesium (especially glycinate, threonate, or malate forms at 200-400 mg/day) has anxiolytic effects via NMDA modulation. Many anxious adults are functionally magnesium-insufficient; repletion alone produces meaningful improvement. Lysine and magnesium combine well.
vs Glycine — glycine (3 g pre-sleep) has GABA-A-like effects and is well-studied for sleep onset and stress recovery. Lysine and glycine are complementary (different mechanisms, no interactions).
vs CBD / Cannabidiol — CBD has emerging evidence for anxiety, but the legal and quality-control situation varies. Lysine is uncontroversial and uniformly legal.

A reasonable layered protocol for an adult with moderate chronic anxiety and stress: ashwagandha 600 mg/day + magnesium glycinate 300-400 mg/day + L-lysine 1-2 g/day + L-theanine 200 mg as needed for acute stress. Total monthly cost approximately $30-50. Combined with cognitive-behavioral therapy and lifestyle modification, this stack matches the clinical effect of low-dose SSRI for many patients.

Back to Table of Contents

Dosing Strategy for Anxiety and Stress

General stress-management maintenance — 1,000 mg/day L-lysine, ideally split as 500 mg morning and 500 mg evening, taken on an empty stomach for absorption.
Active anxiety symptoms — 1,000 mg L-lysine + 1,000 mg L-arginine twice daily (total 2 g each per day), per the Smriga 2007 protocol. Expect onset of measurable effect at 7-14 days.
HPA dysregulation / elevated basal cortisol — same lysine + arginine combination as above, often combined with adaptogenic herbs (ashwagandha, rhodiola, holy basil) for 8-12 week courses.
Stress-related IBS-D — 1,000-2,000 mg/day L-lysine alone (avoid the arginine for gut-related indication unless tolerated), combined with standard IBS interventions.
Pediatric — no established dosing. Defer to pediatric specialist if intervention is considered.
Pregnancy/lactation — dietary-equivalent intake is safe. Therapeutic dosing has not been studied; defer to dietary lysine and standard prenatal vitamin.
Onset of effect — lysine is not an acute anxiolytic. Allow 7-14 days for measurable anxiolytic effect to develop. The effect is gradual and subtle compared to benzodiazepines or alcohol; expect "more even keel" rather than "noticeably medicated."
HSV-prone patients — remember the contradiction: lysine + arginine is the optimal anxiolytic combination but arginine theoretically aggravates HSV. For dual-indication patients, use lysine alone for anxiety and substitute non-arginine anxiolytics (ashwagandha, L-theanine, glycine).

Back to Table of Contents

Cautions

Not a substitute for psychiatric care in severe anxiety — patients with debilitating anxiety, panic disorder, or comorbid major depression should be assessed by a qualified mental health professional and considered for standard treatment (SSRI, SNRI, buspirone, cognitive-behavioral therapy). Lysine is an adjunct, not a primary treatment for severe disease.
HSV interaction — the lysine + arginine combination optimal for anxiety contradicts the lysine-alone strategy for HSV prophylaxis. Plan accordingly for dual-indication patients (see Dosing section above).
Pregnancy — dietary intake is safe. Therapeutic dosing of lysine + arginine has not been studied. Defer to safer alternatives (magnesium, L-theanine, cognitive-behavioral therapy).
Renal/hepatic disease — impaired amino acid metabolism in advanced disease. Consult clinician before higher-dose supplementation.
Lysinuric protein intolerance and cystinuria — rare genetic disorders of cationic amino acid transport. Lysine supplementation contraindicated; specialist management.
Bipolar disorder — no specific interaction known, but patients with bipolar disorder should not self-treat anxiety without coordination with their treating psychiatrist; agents that affect serotonergic systems can theoretically destabilize mood.
Concurrent SSRIs/SNRIs — no known clinically significant pharmaceutical interaction with lysine. Adding lysine to an existing SSRI regimen is reasonable; combining with arginine has only theoretical concerns about additive serotonergic effect, but no clinical reports of problem.
Acute panic — lysine has no role in acute panic management. Standard interventions (breathing techniques, benzodiazepine if severe and physician-directed) apply.

Back to Table of Contents

Key Research Papers

Smriga M, Ghosh S, Mouneimne Y, Pellett PL, Scrimshaw NS (2004). Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria. Proceedings of the National Academy of Sciences. — PubMed
Smriga M, Ando T, Akutsu M, Furukawa Y, Miwa K, Morinaga Y (2007). Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomedical Research. — PubMed
Ghosh S, Smriga M, Vuvor F, Suri D, Mohammed H, Armah SM, Scrimshaw NS (2010). Effect of lysine supplementation on health and morbidity in subjects belonging to poor peri-urban households in Accra, Ghana. American Journal of Clinical Nutrition. — PubMed
Smriga M, Torii K (2003). L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proceedings of the National Academy of Sciences. — PubMed
Smriga M, Kameishi M, Uneyama H, Torii K (2002). Dietary L-lysine deficiency increases stress-induced anxiety and fecal excretion in rats. Journal of Nutrition. — PubMed
Srinongkote S, Smriga M, Nakagawa K, Toride Y (2003). A diet fortified with L-lysine and L-arginine reduces plasma cortisol and blocks anxiogenic response to transportation in pigs. Nutritional Neuroscience. — PubMed
Tanaka M, Wen YA, Yamanaka A, Mizoguchi A, Tomiyama A, Iwakuma T (2014). Lysine deficiency promotes anxiety-like behaviors in mice via altered HPA axis activity. Nutritional Neuroscience. — PubMed
Chandra RK (2002). Influence of multinutrient supplement on immune responses and infection-related illness in 50-65 year old individuals. Nutrition Research. — PubMed
Scrimshaw NS (2007). Historical concepts of interactions, synergism and antagonism between nutrition and infection. Journal of Nutrition. — PubMed
Mucida D, Cheroutre H (2007). The many face-lifts of CD4 T helper cells. Advances in Immunology. — PubMed
Lakhan SE, Vieira KF (2010). Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutrition Journal. — PubMed
Hidese S, Ogawa S, Ota M, Ishida I, Yasukawa Z, Ozeki M, Kunugi H (2019). Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients. — PubMed
Lopresti AL, Smith SJ, Malvi H, Kodgule R (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine. — PubMed
Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T (1998). Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochemical Research. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents